TWD 40.9
(0.25%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 84.65 Million TWD | -25.82% |
2022 | 114.13 Million TWD | -27.25% |
2021 | 156.87 Million TWD | -14.89% |
2020 | 184.31 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 89.21 Million TWD | 5.38% |
2024 Q2 | 117.05 Million TWD | 31.2% |
2023 Q2 | 112.37 Million TWD | 2.96% |
2023 FY | 84.65 Million TWD | -25.82% |
2023 Q1 | 109.14 Million TWD | 0.0% |
2023 Q4 | 84.65 Million TWD | -25.68% |
2023 Q3 | 113.9 Million TWD | 1.36% |
2022 Q4 | - TWD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Allied Biotech Corporation | 796.6 Million TWD | 89.373% |
GeneFerm Biotechnology Co., Ltd. | 152.07 Million TWD | 44.332% |
Easywell Biomedicals, Inc. | 386.34 Million TWD | 78.087% |
TTY Biopharm Company Limited | 1.91 Billion TWD | 95.579% |
Synmosa Biopharma Corporation | 2.43 Billion TWD | 96.53% |
Orient EuroPharma Co., Ltd. | 4.84 Billion TWD | 98.252% |
Center Laboratories, Inc. | 5.62 Billion TWD | 98.495% |
Orient Pharma Co., Ltd. | 716.92 Million TWD | 88.191% |
InnoPharmax Inc. | 21.49 Million TWD | -293.781% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 160.83 Million TWD | 47.362% |
Excelsior Biopharma Inc. | 377.4 Million TWD | 77.568% |
DV Biomed Co., Ltd. | 387.69 Million TWD | 78.164% |
Foresee Pharmaceuticals Co., Ltd. | 228.25 Million TWD | 62.911% |
Handa Pharmaceuticals, Inc. | 13.24 Million TWD | -539.418% |
UniPharma Co., Ltd. | 277 Thousand TWD | -30462.816% |
Anxo Pharmaceutical Co., Ltd. | 787.84 Million TWD | 89.254% |
Alar Pharmaceuticals Inc. | 1.4 Million TWD | -5908.446% |
Winston Medical Supply Co., Ltd. | 107.32 Million TWD | 21.122% |
Mercury Biopharmaceutical Corporation | 42.34 Million TWD | -99.908% |
Bioray Biotech Co., Ltd | 69.79 Million TWD | -21.302% |
TSH Biopharm Corporation Limited | 7.84 Million TWD | -979.421% |